Silo Pharma, Inc. (SILO) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Les analystes estiment Bénéfice par action (EPS) de $-0.56 et chiffre d'affaires de $0.00B pour le prochain exercice fiscal.
Historique du Bénéfice par action (EPS): 2024: réel $-1.19 vs est $-0.56 (manqué -112.5%). 2025: réel $-0.50 vs est $-0.70 (dépassé +28.6%). Précision des analystes: 54%.
Estimations du BPA — SILO
54%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.19
vs Est –$0.56
▼ 52.9% off
2025
Actual –$0.50
vs Est –$0.70
▲ 40.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Estimations du CA — SILO
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▲ 0.1% off
2025
Actual $0.000B
vs Est $0.000B
▲ 0.1% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
Les autres consultent aussi
